Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:
  • No longer available  
  • Page 1 ·  Next »

NCT ID: NCT04798066 No longer available - Clinical trials for Post COVID-19 Syndrome

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

Start date: n/a
Phase:
Study type: Expanded Access

This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome. The investigational product will be an add-on treatment to the standard of care.

NCT ID: NCT04498871 No longer available - Clinical trials for Hypereosinophilic Syndrome (HES)

MAP to Provide Access to Nilotinib, for Patients With HES

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this program is to allow access to nilotinib for eligible patients diagnosed with Hypereosinophilic syndrome (HES). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations. The requesting Treating Physician submitted a request for access to drug (often referred to as Compassionate Use) to Novartis which was reviewed and approved by the medical team experienced with the drug and indication. Please refer to the latest Investigator's Brochure (IB) or approved label for overview of drug including: non-clinical and clinical experience, risk and benefits. Novartis will continue to provide any new safety information to the Treating Physician as they emerge.

NCT ID: NCT04484363 No longer available - Clinical trials for Myelodysplastic Syndromes

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Start date: n/a
Phase:
Study type: Expanded Access

Participants in the expanded access program are adults with higher-risk myelodysplastic syndromes who have no other treatment options available. The main aim of this program is to allow participants to have access to pevonedistat before FDA approval. This program will take place in the United States.

NCT ID: NCT04476706 No longer available - Clinical trials for Cytokine Release Syndrome in COVID-19-induced Pneumonia

Canakinumab MAP in COVID-19 Pneumonia With CRS

Start date: n/a
Phase:
Study type: Expanded Access

This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia

NCT ID: NCT04366830 No longer available - Clinical trials for Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

Start date: n/a
Phase:
Study type: Expanded Access

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).

NCT ID: NCT04355494 No longer available - COVID-19 Clinical Trials

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides access to eculizumab treatment for participants with severe COVID-19.

NCT ID: NCT02968953 No longer available - Clinical trials for Glucose Transporter 1 Deficiency Syndrome

Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome

Start date: n/a
Phase:
Study type: Expanded Access

This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.

NCT ID: NCT02239276 No longer available - Dravet Syndrome Clinical Trials

Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access use of Stiripentol in Dravet Syndrome or epileptic encephalopathies associated with sodium channel mutations who have failed other drugs in an effort to give them the best chance at seizure control and quality of life. As a treatment protocol and not a research study, children will only be monitored on a clinical basis for seizure improvement and side effects predominantly by parent and caregiver report.

NCT ID: NCT02189720 No longer available - Clinical trials for Congenital Myasthenic Syndrome

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

EAP-001
Start date: n/a
Phase:
Study type: Expanded Access

Primary: The primary objective of this study under the original protocol was to provide neuromuscular specialists and neurologists access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus until the product became commercially available. Secondary: The secondary objective of this study under the original protocol was to provide additional long-term safety data on amifampridine phosphate in patients. Primary The primary objective of this study after its fifth amendment was to provide access to amifampridine phosphate therapy to pediatric patients with LEMS, and pediatric and adult patients with CMS until the product became commercially available for these indications or development of the product for the indication was terminated. Secondary: The secondary objective of this study after its fifth amendment was to assess the long-term safety of amifampridine phosphate in pediatric patients with LEMS, and pediatric and adult patients with CMS.

NCT ID: NCT02018302 No longer available - Clinical trials for Glucose Transporter Type 1 Deficiency Syndrome

Post Study Continuation of C7 for G1D

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides ongoing access to triheptanoin for patients who did complete an initial pilot protocol, and provides the opportunity to collect long-term safety data from patients treated with triheptanoin.